Erratum: Expression of Concern: Evidence that Vpu Modulates HIV-1 Gag-Envelope Interaction towards Envelope Incorporation and Infectivity in a Cell Type Dependent Manner (PLoS ONE (2013) 8:4 (e61388) DOI: 10.1371/journal.pone.0061388);Evidence that Vpu Modulates HIV-1 Gag-Envelope Interaction towards Envelope Incorporation and Infectivity in a Cell Type Dependent Manner

PLoS ONE

Volumn 8, Issue 4, 2013, Pages 1-5

  Gautam, Archana ^a   Bhattacharya, Jayanta ^a,b  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN; GLUTAMIC ACID; LEUCINE; VPU PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MOLECULAR INTERACTION; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; START CODON; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS PARTICLE;

EID: 84876176828     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0301303     Document Type: Erratum

References (56)

1. Neil SJ, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
2. Maldarelli F, Chen MY, Willey RL, Strebel K, (1993) Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol 67: 5056-5061.
3. Schwartz S, Felber BK, Fenyo EM, Pavlakis GN, (1990) Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol 64: 5448-5456.
4. Schwartz S, Felber BK, Pavlakis GN, (1992) Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs. Mol Cell Biol 12: 207-219.
5. Schubert U, Bour S, Willey RL, Strebel K, (1999) Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol 73: 887-896.
6. Stephens EB, McCormick C, Pacyniak E, Griffin D, Pinson DM, et al. (2002) Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques. Virology 293: 252-261.
7. Willey RL, Maldarelli F, Martin MA, Strebel K, (1992) Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66: 7193-7200.
8. Strebel K, Klimkait T, Maldarelli F, Martin MA, (1989) Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 63: 3784-3791.
9. Levesque K, Zhao YS, Cohen EA, (2003) Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem 278: 28346-28353.
10. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD, (2006) HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2: e39.
11. Van Damme N, Guatelli J, (2008) HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes. Cell Microbiol 10: 1040-1057.
12. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P, (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 100: 15154-15159.
13. Balliet JW, Kolson DL, Eiger G, Kim FM, McGann KA, et al. (1994) Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. Virology 200: 623-631.
14. Kawamura M, Ishizaki T, Ishimoto A, Shioda T, Kitamura T, et al. (1994) Growth ability of human immunodeficiency virus type 1 auxiliary gene mutants in primary blood macrophage cultures. J Gen Virol 75 (Pt 9): 2427-2431.
15. Dejucq N, Simmons G, Clapham PR, (2000) T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. J Gen Virol 81: 2899-2904.
16. Adachi A, Miyaura M, Sakurai A, Yoshida A, Koyama AH, et al. (2001) Growth characteristics of SHIV without the vpu gene. Int J Mol Med 8: 641-644.
17. Pacyniak E, Gomez ML, Gomez LM, Mulcahy ER, Jackson M, et al. (2005) Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi complex and its absence in the Vpu protein from a subtype C HIV-1. AIDS Res Hum Retroviruses 21: 379-394.
18. Varthakavi V, Smith RM, Martin KL, Derdowski A, Lapierre LA, et al. (2006) The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7: 298-307.
19. Deora A, Spearman P, Ratner L, (2000) The N-terminal matrix domain of HIV-1 Gag is sufficient but not necessary for viral protein U-mediated enhancement of particle release through a membrane-targeting mechanism. Virology 269: 305-312.
20. Callahan MA, Handley MA, Lee YH, Talbot KJ, Harper JW, et al. (1998) Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family. J Virol 72: 8461.
21. Vincent MJ, Abdul Jabbar M, (1995) The human immunodeficiency virus type 1 Vpu protein: a potential regulator of proteolysis and protein transport in the mammalian secretory pathway. Virology 213: 639-649.
22. Lama J, Mangasarian A, Trono D, (1999) Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 9: 622-631.
23. Cortes MJ, Wong-Staal F, Lama J, (2002) Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells. J Biol Chem 277: 1770-1779.
24. Freed EO, Martin MA, (1996) Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 70: 341-351.
25. Freed EO, Martin MA, (1995) Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 69: 1984-1989.
26. Brandano L, Stevenson M, (2012) A highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particles. J Virol 86: 2347-2359.
27. Facke M, Janetzko A, Shoeman RL, Krausslich HG, (1993) A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol 67: 4972-4980.
28. Reicin AS, Paik S, Berkowitz RD, Luban J, Lowy I, et al. (1995) Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol 69: 642-650.
29. Dorfman T, Mammano F, Haseltine WA, Gottlinger HG, (1994) Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 68: 1689-1696.
30. Yu X, Yuan X, Matsuda Z, Lee TH, Essex M, (1992) The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 66: 4966-4971.
31. Wang CT, Zhang Y, McDermott J, Barklis E, (1993) Conditional infectivity of a human immunodeficiency virus matrix domain deletion mutant. J Virol 67: 7067-7076.
32. Bhattacharya J, A Repik, Clapham PR, (2006) Gag Regulates Association of Human Immunodeficiency Virus Type 1 Envelope with Detergent-Resistant Membranes. J Virol 80: 5292-5300.
33. Harila K, Prior I, Sjoberg M, Salminen A, Hinkula J, et al. (2006) Vpu and Tsg101 regulate intracellular targeting of the human immunodeficiency virus type 1 core protein precursor Pr55gag. J Virol 80: 3765-3772.
34. Richards KH, Clapham PR, (2007) Effects of vpu start-codon mutations on human immunodeficiency virus type 1 replication in macrophages. J Gen Virol 88: 2780-2792.
35. Handley MA, Paddock S, Dall A, Panganiban AT, (2001) Association of Vpu-binding protein with microtubules and Vpu-dependent redistribution of HIV-1 Gag protein. Virology 291: 198-207.
36. Lee YH, Schwartz MD, Panganiban AT, (1997) The HIV-1 matrix domain of Gag is required for Vpu responsiveness during particle release. Virology 237: 46-55.
37. Miyagi E, Andrew AJ, Kao S, Strebel K, (2009) Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A 106: 2868-2873.
38. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, et al. (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139: 499-511.
39. Nydegger S, Khurana S, Krementsov DN, Foti M, Thali M, (2006) Mapping of tetraspanin-enriched microdomains that can function as gateways for HIV-1. J Cell Biol 173: 795-807.
40. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, et al. (2001) Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107: 55-65.
41. Martin-Serrano J, Zang T, Bieniasz PD, (2001) HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 7: 1313-1319.
42. Strack B, Calistri A, Craig S, Popova E, Gottlinger HG, (2003) AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114: 689-699.
43. Harila K, Salminen A, Prior I, Hinkula J, Suomalainen M, (2007) The Vpu-regulated endocytosis of HIV-1 Gag is clathrin-independent. Virology 369: 299-308.
44. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM, (1990) The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 64: 621-629.
45. Pelchen-Matthews A, Kramer B, Marsh M, (2003) Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol 162: 443-455.
46. Dutta S, Tan YJ, (2008) Structural and functional characterization of human SGT and its interaction with Vpu of the human immunodeficiency virus type 1. Biochemistry 47: 10123-10131.
47. Ruiz A, Hill MS, Schmitt K, Stephens EB, (2010) Membrane raft association of the Vpu protein of human immunodeficiency virus type 1 correlates with enhanced virus release. Virology 408: 89-102.
48. Joshi A, Ablan SD, Soheilian F, Nagashima K, Freed EO, (2009) Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment. J Virol 83: 5375-5387.
49. Willey SJ, Reeves JD, Hudson R, Miyake K, Dejucq N, et al. (2003) Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells. J Virol 77: 6138-6152.
50. Freed EO, Englund G, Martin MA, (1995) Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol 69: 3949-3954.
51. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J, (2002) HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 18: 567-576.
52. Ringe R, Thakar M, Bhattacharya J, (2010) Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naive Indian patients with recent infection. Retrovirology 7: 76.
53. Gharu L, Ringe R, Bhattacharya J, (2011) HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779. Virus Res 158: 216-224.
54. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, et al. (2004) Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol 78: 6915-6926.
55. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, et al. (2009) Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 83: 9672-9681.
56. Goidin D, Mamessier A, Staquet MJ, Schmitt D, Berthier-Vergnes O, (2001) Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and beta-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal Biochem 295: 17-21.